Emerging therapeutic benefit of platelet-rich fibrin as novel platelet concentrates in tissue engineering.

Treating irreversible cardiomyocyte loss following myocardial infarction presents several therapeutic challenges. While cell therapy shows promise as a regenerative treatment for infarcted cardiac tissue, different cell sources vary in their therapeutic potential. Adipose-derived stem cells (ADSCs) have emerged as an attractive option due to their accessibility, but their limited differentiation capacity remains a significant constraint.

The Role of Human Platelet-rich Plasma to Enhance the Differentiation of Adipose-derived Mesenchymal Stem Cells into Cardiomyocyte: An Experimental Study.

Background: Several studies have shown that adipose-derived mesenchymal stem cells (AMSCs) can differentiate into mesenchymal lineages, including cardiac cell types, but complete differentiation into cardiomyocytes is challenging. Unfortunately, the optimal method to maximize AMSCs differentiation has not yet been established. Platelet-rich plasma (PRP), which contains rich growth factors, is believed to stimulate stem cell proliferation and differentiation in the context of cardiac tissue regeneration.

Inflammation, Immunity, and Hypertension.

The immune system, inflammation and hypertension are related to each other. Innate and adaptive immunity system triggers an inflammatory process, in which blood pressure may increase, stimulating organ damage. Cells in innate immune system produce ROS, such as superoxide and hydrogen peroxide, which aimed at killing pathogens.